Yesterday, my younger son Max, who is 28 years old, went to the funeral of a fraternity brother. Actually, the young man, Andrew, had been a member of his pledge class at the University of Michigan. Andrew, who was also 28 years old, died of Pediatric Brain Cancer. Andrew had battled this disease for over [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]
Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence [...]
